| Baveno VII–renewing consensus in portal hypertension R De Franchis, J Bosch, G Garcia-Tsao, T Reiberger, C Ripoll, ... Journal of hepatology 76 (4), 959-974, 2022 | 1749 | 2022 |
| TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration L Benajiba, I Le Ber, A Camuzat, M Lacoste, C Thomas‐Anterion, ... Annals of neurology 65 (4), 470-473, 2009 | 358 | 2009 |
| The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia N Fenouille, CF Bassil, I Ben-Sahra, L Benajiba, G Alexe, A Ramos, ... Nature medicine 23 (3), 301-313, 2017 | 109 | 2017 |
| High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib T Barbui, AM Vannucchi, A Alvarez-Larran, A Iurlo, A Masciulli, ... Leukemia 35 (2), 485-493, 2021 | 91 | 2021 |
| Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity M Mencarelli, B Dubern, R Alili, S Maestrini, L Benajiba, M Tagliaferri, ... Human molecular genetics 20 (2), 392-399, 2011 | 90 | 2011 |
| Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia FF Wagner, L Benajiba, AJ Campbell, M Weïwer, JR Sacher, JP Gale, ... Science translational medicine 10 (431), eaam8460, 2018 | 88 | 2018 |
| Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2 … AM Risitano, A Röth, J Soret, C Frieri, FS de Fontbrune, L Marano, ... The Lancet Haematology 8 (5), e344-e354, 2021 | 86 | 2021 |
| Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in … X Leleu, G Fouquet, B Hebraud, M Roussel, D Caillot, ML Chrétien, ... Leukemia 27 (11), 2242-2244, 2013 | 76 | 2013 |
| French Clinical and Genetic Research Network on Frontotemporal Lobar Degeneration/Frontotemporal Lobar Degeneration with Motoneuron Disease. TARDBP mutations in motoneuron … L Benajiba, I Le Ber, A Camuzat, M Lacoste, C Thomas-Anterion, ... Ann Neurol 65 (4), 470-473, 2009 | 51 | 2009 |
| Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease LP Zhao, M Boy, C Azoulay, E Clappier, M Sébert, L Amable, J Klibi, ... Leukemia 35 (9), 2720-2724, 2021 | 49 | 2021 |
| Evaluation of improved glycogen synthase kinase-3α inhibitors in models of acute myeloid leukemia T Neumann, L Benajiba, S Göring, K Stegmaier, B Schmidt Journal of medicinal chemistry 58 (22), 8907-8919, 2015 | 39 | 2015 |
| Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor B Roux, C Vaganay, JD Vargas, G Alexe, C Benaksas, B Pardieu, ... Science translational medicine 13 (587), eabg1168, 2021 | 38 | 2021 |
| Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 T Barbui, V De Stefano, A Alvarez-Larran, A Iurlo, A Masciulli, A Carobbio, ... Blood cancer journal 11 (2), 21, 2021 | 38 | 2021 |
| HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine L Benajiba, C Salvado, JH Dalle, C Jubert, C Galambrun, J Soulier, ... Blood, The Journal of the American Society of Hematology 125 (2), 417-418, 2015 | 34 | 2015 |
| Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms C Marcault, LP Zhao, N Maslah, E Verger, R Daltro de Oliveira, ... Blood, The Journal of the American Society of Hematology 138 (21), 2142-2148, 2021 | 25 | 2021 |
| Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission RD De Oliveira, J Soret-Dulphy, LP Zhao, C Marcault, N Gauthier, ... Blood 136, 35-36, 2020 | 25 | 2020 |
| Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts JM Ellegast, G Alexe, A Hamze, S Lin, HJ Uckelmann, PJ Rauch, ... Cancer discovery 12 (7), 1760-1781, 2022 | 24 | 2022 |
| P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia KH Lin, JC Rutter, A Xie, ST Killarney, C Vaganay, C Benaksas, F Ling, ... Nature cancer 3 (7), 837-851, 2022 | 22 | 2022 |
| Long-term follow-up of recovered MPN patients with COVID-19 T Barbui, A Iurlo, A Masciulli, A Carobbio, A Ghirardi, G Rossi, C Harrison, ... Blood Cancer Journal 11 (6), 115, 2021 | 16 | 2021 |
| Second versus first wave of COVID-19 in patients with MPN T Barbui, A Iurlo, A Masciulli, A Carobbio, A Ghirardi, G Carioli, MA Sobas, ... Leukemia 36 (3), 897-900, 2022 | 15 | 2022 |
